Navigation Links
Biodesix Announces New VeriStrat® Data to be Presented at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium
Date:11/22/2011

BROOMFIELD, Colo., Nov. 22, 2011 /PRNewswire/ -- Biodesix today announced  that results from a prospectively designed, retrospective analysis of serum samples from the phase III study, EGF30008, will be presented at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS).  The purpose of the study was to evaluate the ability of the diagnostic test, VeriStrat, to predict patient outcomes following treatment with either Femara ® or Femara in combination with Tykerb ® in patients with metastatic breast cancer. 

VeriStrat, a blood-based proteomic test, is currently used by physicians to help them guide treatment for patients with previously treated advanced non-small cell lung cancer (NSCLC).  The test identifies patients who are likely to have good or poor survival outcomes following treatment with EGFR-TKIs, such as Tarceva®.  VeriStrat has been evaluated in several lung cancer trials, including the phase III registrational trial of Tarceva in advanced NSCLC.

The data will be presented during General Session 1 at the SABCS in San Antonio, TX on Wednesday, December 7th, 2011 at 10:15 AM CST.

For more information on the location of the presentation, visit www.sabcs.org.

About VeriStrat
VeriStrat is a serum proteomic test currently available for patients with advanced NSCLC.  The test identifies patients who are likely to have good or poor outcomes after treatment with epidermal growth factor receptor inhibitors (EGFRIs).  Samples are processed in Biodesix' CLIA accredited laboratory and results are typically reported within 72 hours of sample shipment.  VeriStrat has been validated in clinical studies with over 1500 patients.  For more information on VeriStrat or to order VeriStrat, visit www.VeriStratSupport.com or call the VeriStrat Support Hotline at 1-866-432-5930.

About Biodesix
Biodesix is a personalized medicine company focused on the development of diagnostic products that inform treatment decisions and improve patient care.  The Company's goal is to give physicians more information about the patient and their disease; understanding the clinically meaningful information contained within each patient's molecular profile leads to better care and better outcomes. The Company's unique approach is based on ProTS®, proprietary technology which exploits the power of mass spectrometry and enables the discovery of specific molecular profiles. Biodesix collaborates with clinical investigators to address critical clinical questions, and partners with biotechnology and pharmaceutical companies to develop diagnostics to select patients most likely to benefit from novel therapies. For more information about Biodesix, please visit www.Biodesix.com.

Femara® is a registered trademark of Novartis International AG.

Tykerb® is a registered trademark of the GlaxoSmithKline group of companies in the United States and the countries outside of Europe.

Tarceva® is a registered trademark of OSI Pharmaceuticals, LLC, a member of the Astellas Pharma Global Development Inc. group of companies.

This press release contains statements that are hereby identified as "forward-looking statements" for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the Company's inability to further identify, develop and achieve commercial success for products and technologies; the risk that the Company's financial resources will be insufficient to meet the Company's business objectives; uncertainties relating to the regulatory approval process and changes in relationships with strategic partners. We disclaim any intent or obligation to update these forward-looking statements.


'/>"/>
SOURCE Biodesix
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Biodesix Supports Unique Lung Cancer Research Initiative
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/5/2017)... -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ... pharmaceutical company focused on the development of oral drug delivery ... Israel Securities Authority to dual-list its common stock on the ... trading on the TASE on July 12, 2017 under the ... Company, it is expected that Oramed will be included in ...
(Date:6/30/2017)... , June 30, 2017  AVACEN Medical (AVACEN) announced the ... The research describes the use of its AVACEN Treatment Method ... suffering from fibromyalgia. ... AVACEN Medical ... characterized by chronic widespread pain. It affects approximately 200 to 400 million ...
(Date:6/20/2017)... , June 19, 2017  Hill-Rom Holdings, Inc. (NYSE: ... call and webcast on Friday, July 28, 2017, beginning at ... Call Audio Only Dial-in information: To participate in the conference ... dial into the call at least 10 minutes prior to ... is 34090339.  Webcast: ...
Breaking Medicine Technology:
(Date:7/18/2017)... ... July 18, 2017 , ... ... commercialization, has just announced two more sessions of its “From the Helm” Webinar ... management activities. Led by David Cronin, Cognition’s CEO, the half-hour public webinars will ...
(Date:7/18/2017)... PA (PRWEB) , ... July 18, 2017 , ... An ... control excessive sweating. "Due to menopause, I have frequent hot flashes, and I suffer ... effective but inconspicuous way to keep cool while out and about." INSTA-FAN meets that ...
(Date:7/18/2017)... (PRWEB) , ... July 18, 2017 , ... FCPX LUT ... cooler tones any media. FCPX LUT Berlin includes 60 different color-grade presets, giving FCPX ... distorted looks, vignettes and blurs to emphasize each subject, plus much more. FCPX LUT ...
(Date:7/17/2017)... Greenwich, Connecticut (PRWEB) , ... July 17, 2017 ... ... not too late for parents and camp staff to ensure children are protected ... of Lyme disease this year, children are at an increased risk not only ...
(Date:7/17/2017)... ... 17, 2017 , ... Jordan Search Consultants (JSC), a national ... for Springfield Clinic’s Chief Executive Officer (CEO) in Springfield, IL. Working with JSC ... with more than 30 years of experience, as the new CEO. , ...
Breaking Medicine News(10 mins):